This study is looking at whether adding a drug called Docetaxel to the regular treatment can help lower the chance of prostate cancer growing or spreading. The usual treatment involves hormone therapy. This trial compares the results of adding Docetaxel to the standard hormone therapy with another group that only receives the standard treatment.
The trial's ID is NCT06592924. This is a Phase 3 trial, meaning it is looking at how well the treatment works and how safe it is. It is FDA-regulated and aims to include about 830 participants.
Who can join
Men aged 18 and older with confirmed prostate cancer are eligible. They should have received hormone therapy for at least 6 months but no more than 12 months. Participants should have a specific PSA level and must be able to provide consent. The trial team will check if each person meets the eligibility criteria before joining.
Condition
Prostate Cancer (Adenocarcinoma)
Age group
Adult, Older adult
Sex
Male
The study team makes the final call on eligibility.
What happens in the study
Participants will be randomly placed into one of two groups. One group will receive the standard treatment, which includes hormone therapy and an Androgen-Receptor Pathway Inhibitor. The other group will receive the same standard treatment plus Docetaxel. Everyone will be monitored throughout the trial.
Where
This trial is enrolling at 350 locations. Recruiting sites are listed first.
Directs translational prostate cancer research, MSK. Treats prostate cancer, bladder cancer, testicular cancer and penile cancer. Also treats kidney cancer.
Leads translational research at Masonic Cancer Center. Treats prostate cancer. The main cancer doctor for adults. Manages your treatment and your care team. Recognized at state, national or international level.
Vice Chair of Urology and Robotic Operations and Director of the Comprehensive Kidney Cancer Program. Treats bladder cancer, penile cancer, prostate cancer and testicular cancer. Also treats kidney cancer.